Peak Human ShopOral GLP-1 (Orforglipron)
30 Capsules · 3 mg per capsule · 1-month supply
The first non-peptide, oral GLP-1 receptor agonist proven in Phase 3 trials to deliver weight loss and metabolic regulation comparable to injectable GLP-1s — without needles, refrigeration, or fasting windows.
Oral capsule
No injections, no refrigeration
Non-peptide
Small-molecule GLP-1 receptor agonist
Daily dose
1 capsule — no fasting required
Physician-vetted
Curated by Dr. Sanjeev Goel
$145.00
on Peak Human ShopA small molecule with peptide-grade results.
Selectively activates the GLP-1 receptor like semaglutide and tirzepatide — but as a small molecule, not a peptide.
Slows gastric emptying, increases satiety, and improves glucose-dependent insulin secretion.
Oral bioavailability without food or water restrictions thanks to its non-peptide structure.
Half-life supports once-daily dosing with stable plasma levels.
Backed by Phase 2 & Phase 3 trials in NEJM and The Lancet.
Orforglipron has been studied in over a dozen registered clinical trials. Below are the peer-reviewed publications most relevant to weight management and metabolic regulation.
New England Journal of Medicine, 2025
Efficacy and Safety of Orforglipron in Adults with Obesity (ATTAIN-1)
Aronne LJ, et al.
Phase 3 trial in adults with obesity showed mean weight reduction of ~12.4% at the 36 mg dose over 72 weeks vs. placebo, with improvements in waist circumference and cardiometabolic markers.
Read studyNew England Journal of Medicine, 2025
Once-Daily Oral Orforglipron in Adults with Type 2 Diabetes (ACHIEVE-1)
Frias JP, et al.
Phase 3 trial demonstrated HbA1c reductions of up to 1.5% and weight loss of ~7.6% at 40 weeks, with a safety profile comparable to injectable GLP-1 agonists.
Read studyNew England Journal of Medicine, 2023; 389:877–888
Efficacy and Safety of an Oral Small-Molecule GLP-1 Receptor Agonist in Adults with Obesity
Wharton S, et al.
Phase 2 trial established orforglipron as the first oral non-peptide GLP-1 RA with weight loss up to 14.7% at 36 weeks across dose escalation.
Read studyThe Lancet, 2023; 402(10400):472–483
Orforglipron, a Novel Oral Nonpeptide GLP-1 Receptor Agonist, for Type 2 Diabetes
Frias JP, et al.
26-week Phase 2 trial in T2D showed dose-dependent reductions in HbA1c (up to −2.10%) and body weight (up to −10.1 kg).
Read studyA physician-supervised protocol.
Orforglipron is an investigational compound. Peak Human products are intended for adults under the guidance of a qualified healthcare provider. This page summarizes published clinical evidence and is not medical advice. Individual results vary, and GLP-1 receptor agonists carry potential side effects including nausea, gastrointestinal discomfort, and rare risk of pancreatitis.
If you are a current patient or VIP member, discuss the Oral GLP-1 protocol with your care team before starting.
Oral GLP-1 (Orforglipron) — curated by Dr. Goel.
Ships from Peak Human Shop. One capsule daily, no fasting, no needles.